Reference(s)
Click here to return to the Reference Table

Cancer type: Colorectal


HGF/SF expression

Reference Number: 31
Fukuura, T., Miki, C., Inoue, T., Matsumoto, K. & Suzuki, H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer 78, 454-9. (1998).
PubMed link      E-mail link

Reference Number: 32
Otte, J. M. et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61, 237-46 (2000).
PubMed link      E-mail link

Reference Number: 362
Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T, Yamagishi H. Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res. 25, 3847-54 (2005) Erratum in: Anticancer Res. 26, 445 (2006)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 437
Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer.  41, 555-63(2005)
PubMed link      E-mail link

Reference Number: 479
Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene. 26, 1078-87 (2007)
PubMed link      E-mail link

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 481
Jie JZ, Wang JW, Qu JG, Wang W, Hung T. Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro. World J Gastroenterol. 12, 3983-8 (2006)
PubMed link      E-mail link

Reference Number: 482
Fassetta M, D'Alessandro L, Coltella N, Di Renzo MF, Rasola A. Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal. 18, 1967-76 (2006)
PubMed link      E-mail link

Reference Number: 485
Inoue Y, Miki C, Watanabe H, Ojima E, Kusunoki M. Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. Surgery. 139, 305-11 (2006)
PubMed link      E-mail link

Reference Number: 564
Zhang YH, Wei W, Xu H, Wang YY, Wu WX. Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways. Chin Med J (Engl). 120, 743-8 (2007)
PubMed link      E-mail link

Reference Number: 590
Baldus SE, Kort EJ, Schirmacher P, Dienes HP, Resau JH. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol. 31, 199-204 (2007)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 855
Paduch R, Jakubowicz-Gil J, Niedziela P. Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11). Indian J Exp Biol. 48, 354-64 (2010)
PubMed link      E-mail link

Reference Number: 875
Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 125, 1657-62 (2009)
PubMed link      E-mail link

Reference Number: 876
Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC, Paraskeva C. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis. 30, 1796-804 (2009)
PubMed link      E-mail link

Reference Number: 1062
Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 40, 583-91 (2012)
PubMed link      E-mail link

Reference Number: 1063
Kumara HM, Tohme ST, Kim IY, Kim DG, Kalady MF, Luchtefeld M, Hoffman K, Dimaggio V, Whelan RL. Minimally invasive colorectal resection is associated with a transient increase in plasma hepatocyte growth factor levels early after surgery for colon cancer. Surg Innov. 18, 254-8 (2011)
PubMed link      E-mail link

Reference Number: 1201
Tian M, Yu L, Zhang Y, Gao X. Correlations between SUVmax and expression of GLUT1 and growth factors inducing lymphangiogenesis. Acad Radiol. 19, 420-6 (2012)
PubMed link      E-mail link

Reference Number: 1345
Sun YL1, Liu WD, Ma GY, Gao DW, Jiang YZ, Liu Q, Du JJ. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis. Int J Med Sci. 10, 548-59 (2013)
PubMed link      E-mail link

Reference Number: 1387
Tanahashi T1, Osada S, Yamada A, Kato J, Yawata K, Mori R, Imai H, Sasaki Y, Saito S, Tanaka Y, Nonaka K, Yoshida K. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition. Int J Oncol. 42, 556-64 (2013)
PubMed link      E-mail link

Reference Number: 1389
Matsumura A1, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K, Otsuji E. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. Int J Oncol. 42, 535-42 (2013)
PubMed link      E-mail link

Reference Number: 1447
Takahashi N1, Yamada Y1, Furuta K2, Honma Y1, Iwasa S1, Takashima A1, Kato K1, Hamaguchi T1, Shimada Y1. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer. 110, 2716-27 (2014)
PubMed link      E-mail link

Reference Number: 1494
Swietlicki EA, Bala S, Lu J, Shaker A, Kularatna G, Levin MS, Rubin DC. Epimorphin deletion inhibits polyposis in the Apcmin/ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion. Am J Physiol Gastrointest Liver Physiol. 305, G564-72 (2013)
PubMed link      E-mail link

Reference Number: 1588
Seneviratne D, Ma J, Tan X, Kwon YK, Muhammad E, Melhem M, DeFrances MC, Zarnegar R Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology. 48, 181-191.e17 (2015)
PubMed link      E-mail link

Reference Number: 1709
Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. Anticancer Res. 35, 1683-9 (2015)
PubMed link      E-mail link

Reference Number: 1734
Bigatto V, De Bacco F, Casanova E, Reato G, Lanzetti L, Isella C, Sarotto I, Comoglio PM, Boccaccio C TNF-a promotes invasive growth through the MET signaling pathway. Mol Oncol. 9, 377-88 (2015)
PubMed link      E-mail link

Reference Number: 1759
Hinz S, Tepel J, Röder C, Kalthoff H, Becker T. Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases - a pilot study. Anticancer Res. 35, 2961-7 (2015)
PubMed link      E-mail link

Reference Number: 1760
Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci. 106, 604-10 (2015)
PubMed link      E-mail link

Reference Number: 1824
Li F, Zhu YT. HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling. Cell Signal. 27, 860-6 (2015)
PubMed link      E-mail link

Met expression

Reference Number: 32
Otte, J. M. et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61, 237-46 (2000).
PubMed link      E-mail link

Reference Number: 33
Di Renzo, M. F. et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1, 147-54. (1995).
PubMed link      E-mail link

Reference Number: 34
Fazekas, K., Csuka, O., Koves, I., Raso, E. & Timar, J. Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin Exp Metastasis 18, 639-49 (2000).
PubMed link      E-mail link

Reference Number: 35
Fujita, S. & Sugano, K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 27, 378-83. (1997).
PubMed link      E-mail link

Reference Number: 36
Liu, C., Park, M. & Tsao, M. S. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 7, 181-5. (1992).
PubMed link      E-mail link

Reference Number: 311
Boon EM, Kovarikova M, Derksen PW, van der Neut R. MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. Br J Cancer92, 1078-83 (2005)

PubMed link      E-mail link

Reference Number: 479
Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene. 26, 1078-87 (2007)
PubMed link      E-mail link

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 483
Singh R, Subramanian S, Rhodes JM, Campbell BJ. Peanut lectin stimulates proliferation of colon cancer cells by interaction with glycosylated CD44v6 isoforms and consequential activation of c-Met and MAPK: functional implications for disease-associated glycosylation changes. Glycobiology. 16, 594-601 (2006)
PubMed link      E-mail link

Reference Number: 590
Baldus SE, Kort EJ, Schirmacher P, Dienes HP, Resau JH. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol. 31, 199-204 (2007)
PubMed link      E-mail link

Reference Number: 625
Seiden-Long I, Navab R, Shih W, Li M, Chow J, Zhu CQ, Radulovich N, Saucier C, Tsao MS. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis. 29, 647-55 (2008)
PubMed link      E-mail link

Reference Number: 646
Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res. 14, 3814-22 (2008)
PubMed link      E-mail link

Reference Number: 647
Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum. 51, 1268-74 (2008)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 658
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT 4th, D'Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-69 (2008)
PubMed link      E-mail link

Reference Number: 706
Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 15, 59-67 (2009) Epub 2008 Dec 21
PubMed link      E-mail link

Reference Number: 735
Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, Bilchik A, Turner R, Tran A, Kuo C, Hoon DS. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res. 11, 7621-8 (2005)
PubMed link      E-mail link

Reference Number: 799
Nam HJ, Chae S, Jang SH, Cho H, Lee JH. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis. 31, 1531-40 (2010)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 841
Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, Joseph L, Bissonnette M, Khare S. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 29, 5241-53 (2010)
PubMed link      E-mail link

Reference Number: 876
Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC, Paraskeva C. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis. 30, 1796-804 (2009)
PubMed link      E-mail link

Reference Number: 878
De Oliveira AT, Matos D, Logullo AF, DA Silva SR, Neto RA, Filho AL, Saad SS. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 29, 4807-11 (2009)
PubMed link      E-mail link

Reference Number: 917
Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, Lehy T, Aparicio T. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol. 40, 1517-27 (2009)
PubMed link      E-mail link

Reference Number: 931
Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ, Hoon DS. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 9, 1480-8 (2003)
PubMed link      E-mail link

Reference Number: 947
Matsui S, Osada S, Tomita H, Komori S, Mori R, Sanada Y, Takahashi T, Yamaguchi K, Yoshida K. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol. 37, 289-97 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1035
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 9, 166 (2011)
PubMed link      E-mail link

Reference Number: 1050
Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res. 17, 3146-56 (2011)
PubMed link      E-mail link

Reference Number: 1056
Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 10, 325-32 (2011)
PubMed link      E-mail link

Reference Number: 1062
Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 40, 583-91 (2012)
PubMed link      E-mail link

Reference Number: 1067
Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol. 179, 3032-44 (2011)
PubMed link      E-mail link

Reference Number: 1076
van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 11, 355-64 (2009)
PubMed link      E-mail link

Reference Number: 1113
Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Burt RW. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer. 11, 424 (2011)
PubMed link      E-mail link

Reference Number: 1140
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 18, 737-47 (2012)
PubMed link      E-mail link

Reference Number: 1141
Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 32, 1527-31 (2012)
PubMed link      E-mail link

Reference Number: 1157
Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98, 105-12 (2012)
PubMed link      E-mail link

Reference Number: 1290
Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol. 26, 302-13 (2013)
PubMed link      E-mail link

Reference Number: 1295
Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and ß-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 219, 710-20 (2013)
PubMed link      E-mail link

Reference Number: 1328
Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 28, 9-18 (2013)
PubMed link      E-mail link

Reference Number: 1344
Zuo Y1, Ren S, Wang M, Liu B, Yang J, Kuai X, Lin C, Zhao D, Tang L, He F. Novel roles of liver sinusoidal endothelial cell lectin in colon carcinoma cell adhesion, migration and in-vivo metastasis to the liver. Gut. 62, 1169-78 (2013)
PubMed link      E-mail link

Reference Number: 1345
Sun YL1, Liu WD, Ma GY, Gao DW, Jiang YZ, Liu Q, Du JJ. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis. Int J Med Sci. 10, 548-59 (2013)
PubMed link      E-mail link

Reference Number: 1391
Chen HJ1, Jiang YL, Lin CM, Tsai SC, Peng SF, Fushiya S, Hour MJ, Yang JS. Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int J Oncol. 43, 141-50 (2013)
PubMed link      E-mail link

Reference Number: 1424
Deeb KK1, Sram JP, Gao H, Fakih MG. Multigene assays in metastatic colorectal cancer J Natl Compr Canc Netw. 11 Suppl 4:S9-17 (2013)
PubMed link      E-mail link

Reference Number: 1434
Samamé Pérez-Vargas JC1, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio F. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 14, 18056-77 (2013)
PubMed link      E-mail link

Reference Number: 1456
Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother Pharmacol. 73, 749-57 (2014)
PubMed link      E-mail link

Reference Number: 1462
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-73 (2013)
PubMed link      E-mail link

Reference Number: 1471
Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, Goel A. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 63, 635-46 (2014)
PubMed link      E-mail link

Reference Number: 1487
Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata K, Ohue M, Kato T, Takemasa I, Mizushima T, Ishii H, Mimori K, Doki Y, Mori M. Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Mol Cancer Ther. 13, 976-85 (2014)
PubMed link      E-mail link

Reference Number: 1490
Ren B, Zakharov V, Yang Q, McMahon L, Yu J, Cao W. MACC1 is related to colorectal cancer initiation and early-stage invasive growth. Am J Clin Pathol. 140, 701-7 (2013)
PubMed link      E-mail link

Reference Number: 1521
Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 74, 1857-69 (2014)
PubMed link      E-mail link

Reference Number: 1551
Boccaccio C, Luraghi P, Comoglio PM. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer Res. 74, 3647-51 (2014)
PubMed link      E-mail link

Reference Number: 1557
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 124, 3172-86 (2014)
PubMed link      E-mail link

Reference Number: 1561
Apostolou P, Toloudi M, Ioannou E, Kourtidou E, Chatziioannou M, Kopic A, Komiotis D, Kiritsis C, Manta S, Papasotiriou I. Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells. J Recept Signal Transduct Res. 33, 353-8 (2013)
PubMed link      E-mail link

Reference Number: 1562
Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Increased TGF-a as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 19, 6751-65 (2013)
PubMed link      E-mail link

Reference Number: 1585
Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci. 105, 1002-7 (2014)
PubMed link      E-mail link

Reference Number: 1589
Satoh K, Nimura S, Aoki M, Hamasaki M, Koga K, Iwasaki H, Yamashita Y, Kataoka H, Nabeshima K. Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci. 105, 1487-95 (2014)
PubMed link      E-mail link

Reference Number: 1590
Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, Sauvanet P, Darcha C, Déchelotte P, Bonnet M, Pezet D, Wodrich H, Darfeuille-Michaud A, Bonnet R Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 63, 1932-42 (2014)
PubMed link      E-mail link

Reference Number: 1591
Harpaz N, Taboada S, Ko HM, Yu J, Yang Q, Xu H, Cao W. Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia. Inflamm Bowel Dis. 20, 703-11 (2014)
PubMed link      E-mail link

Reference Number: 1632
Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y, Qu X. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci. 15, 5838-51 (2014)
PubMed link      E-mail link

Reference Number: 1633
Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Sugiyama M, Watanabe T. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. Oncol Rep. 32, 57-64 (2014)
PubMed link      E-mail link

Reference Number: 1666
Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H, Zhang C, He Q, Zhang L, Li Z, Zhou D. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PLoS One. 9, e113186 (2014)
PubMed link      E-mail link

Reference Number: 1697
Elliott VA, Rychahou P, Zaytseva YY, Evers BM. Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. PLoS One. 9(5):e97432 (2014)
PubMed link      E-mail link

Reference Number: 1734
Bigatto V, De Bacco F, Casanova E, Reato G, Lanzetti L, Isella C, Sarotto I, Comoglio PM, Boccaccio C TNF-a promotes invasive growth through the MET signaling pathway. Mol Oncol. 9, 377-88 (2015)
PubMed link      E-mail link

Reference Number: 1761
Li J, Bharadwaj SS, Guzman G, Vishnubhotla R, Glover SC. ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. Anticancer Res. 35, 3267-73 (2015)
PubMed link      E-mail link

Reference Number: 1763
Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam M, Kales AJ, Bendiksen R, Indrevoll B, Bjerke RM, Moestue SA, Yazdanfar S, Langers AM, Swaerd-Nordmo M, Torheim G, Warren MV, Morreau H, Voorneveld PW, Buckle T, van Leeuwen FW, Ødegårdstuen LI, Dalsgaard GT, Healey A, Hardwick JC. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 21, 955-61 (2015)
PubMed link      E-mail link

Reference Number: 1766
Cui YM, Jiao HL, Ye YP, Chen CM, Wang JX, Tang N, Li TT, Lin J, Qi L, Wu P, Wang SY, He MR, Liang L, Bian XW, Liao WT, Ding YQ. FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene. 34, 4379-90 (2015)
PubMed link      E-mail link

Reference Number: 1831
Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog. 1, 28-34 (2013)
PubMed link      E-mail link

Reference Number: 1832
Seo AN, Park KU, Choe G, Kim WH, Kim DW, Kang SB, Lee HS. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour Biol. 36, 9813-21 (2015)
PubMed link      E-mail link

Reference Number: 1847
Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Omoto Y, Iwase H. Differential role of MACC1 expression and its regulation of the HGF/c Met pathway between breast and colorectal cancer. Int J Oncol. 46, 2143-53 (2015)
PubMed link      E-mail link

Reference Number: 1862
Sclafani F, Rimassa L, Colombo P, Destro A, Stinco S, Lutman FR, Carnaghi C, Beretta G, Zanello A, Roncalli M, Giordano L, Santoro A. An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. Int J Biol Markers. 30, e73-80 (2015)
PubMed link      E-mail link

Reference Number: 1892
Liu Z, Wei P, Yang Y, Cui W, Cao B, Tan C, Yu B, Bi R, Xia K, Chen W, Wang Y, Zhang Y, Du X, Zhou X. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs. Clin Cancer Res. 21, 1752-63 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 485
Inoue Y, Miki C, Watanabe H, Ojima E, Kusunoki M. Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. Surgery. 139, 305-11 (2006)
PubMed link      E-mail link

Reference Number: 734
Miki C, Inoue Y, Hiro J, Ojima E, Araki T, Uchida K, Kusunoki M. Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes a and B colorectal cancer: results of a five-year study. Dis Colon Rectum. 49, 1710-8 (2006)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 1056
Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 10, 325-32 (2011)
PubMed link      E-mail link

Reference Number: 1157
Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98, 105-12 (2012)
PubMed link      E-mail link

Reference Number: 1328
Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 28, 9-18 (2013)
PubMed link      E-mail link

Reference Number: 1434
Samamé Pérez-Vargas JC1, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio F. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 14, 18056-77 (2013)
PubMed link      E-mail link

Reference Number: 1436
Bendell JC1, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, Hack SP. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 12, 218-22 (2013)
PubMed link      E-mail link

Reference Number: 1447
Takahashi N1, Yamada Y1, Furuta K2, Honma Y1, Iwasa S1, Takashima A1, Kato K1, Hamaguchi T1, Shimada Y1. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer. 110, 2716-27 (2014)
PubMed link      E-mail link

Reference Number: 1656
Lee J, Jain A, Kim P, Lee T, Kuller A, Princen F, In-GuDo, Kim SH, Park JO, Park YS, Singh S, Kim HC. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PLoS One. 9, e103551 (2014)
PubMed link      E-mail link

Reference Number: 1832
Seo AN, Park KU, Choe G, Kim WH, Kim DW, Kang SB, Lee HS. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour Biol. 36, 9813-21 (2015)
PubMed link      E-mail link

Reference Number: 1859
Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol. 21, 3706-10 (2015)
PubMed link      E-mail link

Mutation of Met

Reference Number: 1327
Gawlick U, Lu KC, Douthit MA, Diggs BS, Schuff KG, Herzig DO, Tsikitis VL. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. Am J Surgery 205, 608-12; discussion 612 (2013)
PubMed link      E-mail link

Reference Number: 1390
Jiang L1, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genet. 206, 330-9 (2013)
PubMed link      E-mail link

In vitro studies

Reference Number: 32
Otte, J. M. et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61, 237-46 (2000).
PubMed link      E-mail link

Reference Number: 34
Fazekas, K., Csuka, O., Koves, I., Raso, E. & Timar, J. Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin Exp Metastasis 18, 639-49 (2000).
PubMed link      E-mail link

Reference Number: 37
Wielenga, V. J. et al. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am J Pathol 157, 1563-73. (2000).
PubMed link      E-mail link

Reference Number: 219
Long, I.S. et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 1:393-401 (2003).
PubMed link      E-mail link

Reference Number: 240
Herynk MH, Tsan R, Radinsky R, Gallick GE. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 20:291-300 (2003).
PubMed link      E-mail link

Reference Number: 241
Li XN, Ding YQ, Liu GB. Transcriptional gene expression profiles of HGF/SF-met signaling pathway in colorectal carcinoma. World J Gastroenterol 9:1734-8 (2003).
PubMed link      E-mail link

Reference Number: 242
Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 17:1640-7 (2003).


PubMed link      E-mail link

Reference Number: 311
Boon EM, Kovarikova M, Derksen PW, van der Neut R. MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. Br J Cancer92, 1078-83 (2005)

PubMed link      E-mail link

Reference Number: 362
Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T, Yamagishi H. Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res. 25, 3847-54 (2005) Erratum in: Anticancer Res. 26, 445 (2006)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 457
Seiden-Long IM, Brown KR, Shih W, Wigle DA, Radulovich N, Jurisica I, Tsao MS. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene.  25, 91-102 (2006)
PubMed link      E-mail link

Reference Number: 458
Li HW, Shan JX. Effects of hepatocyte growth factor/scatter factor on the invasion of colorectal cancer cells in vitro. World J Gastroenterol. 11, 3877-81 (2005)
PubMed link      E-mail link

Reference Number: 459
Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg.  241, 748-56; discussion 756-8 (2005)
PubMed link      E-mail link

Reference Number: 460
Miao H, Strebhardt K, Pasquale EB, Shen TL, Guan JL, Wang B. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem280, 923-32 (2005)
PubMed link      E-mail link

Reference Number: 479
Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene. 26, 1078-87 (2007)
PubMed link      E-mail link

Reference Number: 481
Jie JZ, Wang JW, Qu JG, Wang W, Hung T. Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro. World J Gastroenterol. 12, 3983-8 (2006)
PubMed link      E-mail link

Reference Number: 482
Fassetta M, D'Alessandro L, Coltella N, Di Renzo MF, Rasola A. Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal. 18, 1967-76 (2006)
PubMed link      E-mail link

Reference Number: 483
Singh R, Subramanian S, Rhodes JM, Campbell BJ. Peanut lectin stimulates proliferation of colon cancer cells by interaction with glycosylated CD44v6 isoforms and consequential activation of c-Met and MAPK: functional implications for disease-associated glycosylation changes. Glycobiology. 16, 594-601 (2006)
PubMed link      E-mail link

Reference Number: 553
Reshetnikova G, Troyanovsky S, Rimm DL. Definition of a direct extracellular interaction between Met and E-cadherin. Cell Biol Int. 31, 366-73 (2007)
PubMed link      E-mail link

Reference Number: 557
Emaduddin M, Bicknell DC, Bodmer WF, Feller SM. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A. 105, 2358-62 (2008)
PubMed link      E-mail link

Reference Number: 563
Herynk MH, Zhang J, Parikh NU, Gallick GE. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol. 6, 205-17 (2007)
PubMed link      E-mail link

Reference Number: 617
Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68, 1213-20 (2008)
PubMed link      E-mail link

Reference Number: 618
Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther. 6, 2868-78 (2007)
PubMed link      E-mail link

Reference Number: 799
Nam HJ, Chae S, Jang SH, Cho H, Lee JH. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis. 31, 1531-40 (2010)
PubMed link      E-mail link

Reference Number: 841
Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, Joseph L, Bissonnette M, Khare S. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 29, 5241-53 (2010)
PubMed link      E-mail link

Reference Number: 921
Hu G, Chen D, Li X, Yang K, Wang H, Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther. 10, 190-7 (2010)
PubMed link      E-mail link

Reference Number: 1049
Organ SL, Tong J, Taylor P, St-Germain JR, Navab R, Moran MF, Tsao MS. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. J Proteome Res. 10, 3200-11 (2011)
PubMed link      E-mail link

Reference Number: 1140
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 18, 737-47 (2012)
PubMed link      E-mail link

Reference Number: 1240
Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, Gariboldi M, Pierotti MA. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 10, 504-15 (2012)
PubMed link      E-mail link

Reference Number: 1446
Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K3, Tulasne D, Carpén O, Ivaska J. Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev Cell. 29, 421-36 (2014)
PubMed link      E-mail link

Reference Number: 1486
Pomerleau V, Landry M, Bernier J, Vachon PH, Saucier C. Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions. BMC Cancer. 14, 240 (2014)
PubMed link      E-mail link

Reference Number: 1487
Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata K, Ohue M, Kato T, Takemasa I, Mizushima T, Ishii H, Mimori K, Doki Y, Mori M. Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Mol Cancer Ther. 13, 976-85 (2014)
PubMed link      E-mail link

Animal models

Reference Number: 39
Shimizu, S. et al. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res 91, 1285-95. (2000).
PubMed link      E-mail link

Reference Number: 218
Herynk, M.H. et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.  Cancer Res 63:2990-6 (2003).
PubMed link      E-mail link

Reference Number: 219
Long, I.S. et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 1:393-401 (2003).
PubMed link      E-mail link

Reference Number: 311
Boon EM, Kovarikova M, Derksen PW, van der Neut R. MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. Br J Cancer92, 1078-83 (2005)

PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 362
Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T, Yamagishi H. Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res. 25, 3847-54 (2005) Erratum in: Anticancer Res. 26, 445 (2006)
PubMed link      E-mail link

Reference Number: 595
Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem Biophys Res Commun. 358, 117-23 (2007)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1109
Yamaji N, Ido A, Moriuchi A, Numata M, Setoyama H, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice. Oncol Rep. 26, 335-41 (2011)
PubMed link      E-mail link

Reference Number: 1494
Swietlicki EA, Bala S, Lu J, Shaker A, Kularatna G, Levin MS, Rubin DC. Epimorphin deletion inhibits polyposis in the Apcmin/ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion. Am J Physiol Gastrointest Liver Physiol. 305, G564-72 (2013)
PubMed link      E-mail link

Reference Number: 1770
Wang GS, Zhao JL, Li H. Treatment with Lingqi capsules suppresses colorectal cancer by inhibiting the hepatocyte growth factor/c Met signal transduction pathway. Mol Med Rep. 11, 1865-70 (2015)
PubMed link      E-mail link

Reference Number: 1833
Sun Y, Sun L, An Y, Shen X. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model. Med Sci Monit. 21, 2316-21 (2015)
PubMed link      E-mail link

Reference Number: 1886
Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJ, van Doorn L, Hellemans P, de Bono JS, Eskens FA. The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 21, 2297-304 (2015)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 38
Fazekas, K., Raso, E., Zarandi, M., Dudas, J. & Timar, J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 22, 2575-9 (2002).
PubMed link      E-mail link

Reference Number: 218
Herynk, M.H. et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.  Cancer Res 63:2990-6 (2003).
PubMed link      E-mail link

Reference Number: 299
Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T, Yamagishi H. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci 95, 321-7 (2004)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 618
Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther. 6, 2868-78 (2007)
PubMed link      E-mail link

Reference Number: 703
Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 68, 6680-7 (2008)
PubMed link      E-mail link

Reference Number: 715
Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 104, 11412-7 (2007)
PubMed link      E-mail link

Reference Number: 800
Larsen CA, Dashwood RH. (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys. 501, 52-7 (2010)
PubMed link      E-mail link

Reference Number: 877
Larsen CA, Dashwood RH. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide. Biochem Biophys Res Commun. 389, 527-30 (2009)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 972
Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 17, 472-82 (2011)
PubMed link      E-mail link

Reference Number: 1067
Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol. 179, 3032-44 (2011)
PubMed link      E-mail link

Reference Number: 1109
Yamaji N, Ido A, Moriuchi A, Numata M, Setoyama H, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice. Oncol Rep. 26, 335-41 (2011)
PubMed link      E-mail link

Reference Number: 1158
Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012)
PubMed link      E-mail link

Reference Number: 1159
Han SY, Lee CO, Ahn SH, Lee MO, Kang SY, Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, Kim HR, Koh JS, Lee J. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 30, 518-23 (2012)
PubMed link      E-mail link

Reference Number: 1388
Gibbons AV1, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, Waldman SA. Intestinal GUCY2C prevents TGF-ß secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res. 73, 6654-66 (2013)
PubMed link      E-mail link

Reference Number: 1397
Gao W1, Bing X, Li M, Yang Z, Li Y, Chen H. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma. Med Oncol. 30, 546 (2013)
PubMed link      E-mail link

Reference Number: 1436
Bendell JC1, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, Hack SP. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 12, 218-22 (2013)
PubMed link      E-mail link

Reference Number: 1470
Gao SH, Liu C, Wei J, Feng Y. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth. Chin Med J (Engl). 126, 2705-9 (2013)
PubMed link      E-mail link

Reference Number: 1550
Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, Zhu W. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One. 8, e78086 (2013)
PubMed link      E-mail link

Reference Number: 1657
Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 7, 1940-55 (2014)
PubMed link      E-mail link

Reference Number: 1658
Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 136, 1967-75 (2015)
PubMed link      E-mail link

Reference Number: 1765
Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 20, 4240-50 (2014)
PubMed link      E-mail link

Reference Number: 1833
Sun Y, Sun L, An Y, Shen X. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model. Med Sci Monit. 21, 2316-21 (2015)
PubMed link      E-mail link

Reference Number: 1886
Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJ, van Doorn L, Hellemans P, de Bono JS, Eskens FA. The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 21, 2297-304 (2015)
PubMed link      E-mail link

Reviews

Reference Number: 750
Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 41, 2356-9 (2009)
PubMed link      E-mail link

Reference Number: 1681
Gao H, Guan M, Sun Z, Bai C. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumour Biol. 36, 515-20 (2015)
PubMed link      E-mail link